These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 14703923)

  • 1. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
    Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
    Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
    Serinet MO; Jacquemin E; Habes D; Debray D; Fabre M; Bernard O
    J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
    Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
    Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
    Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
    Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.
    Zilz ND; Olson LJ; McGregor CG
    J Heart Lung Transplant; 2001 Jul; 20(7):770-2. PubMed ID: 11448808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-transplant lymphoproliferative disorder--case reports of three children with kidney transplant.
    Spasojević-Dimitrijeva B; Peco-Antić A; Paripović D; Kruscić D; Krstić Z; Cupić M; Cvetković M; Milosevski-Lomić G; Kostić M
    Srp Arh Celok Lek; 2014; 142(1-2):83-8. PubMed ID: 24684038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
    Kuriyama T; Kawano N; Yamashita K; Ueda A
    J Clin Exp Hematop; 2014; 54(2):149-53. PubMed ID: 25318948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.
    Jain AB; Marcos A; Pokharna R; Shapiro R; Fontes PA; Marsh W; Mohanka R; Fung JJ
    Transplantation; 2005 Dec; 80(12):1692-8. PubMed ID: 16378063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Epstein-Barr virus--associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review.
    Zhu K; Chen J; Chen S
    Hematology; 2005 Oct; 10(5):365-70. PubMed ID: 16273722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
    Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation.
    Yedibela S; Reck T; Niedobitek G; Gramatzki M; Repp R; Hohenberger W; Ott R
    Transpl Int; 2003 Mar; 16(3):197-201. PubMed ID: 12664216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presentation and outcomes of post-transplant lymphoproliferative disorder at a single institution pediatric transplant center.
    Ramos-Gonzalez G; Crum R; Allain A; Agur T; O'Melia L; Staffa S; Burchett SK; Siegele B; Weinberg O; Rodig NM; Fawaz R; Singh TP; Freiberger DA; Bae Kim H
    Pediatr Transplant; 2022 Aug; 26(5):e14268. PubMed ID: 35304794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication.
    Verschuuren EA; Stevens SJ; van Imhoff GW; Middeldorp JM; de Boer C; Koëter G; The TH; van Der Bij W
    Transplantation; 2002 Jan; 73(1):100-4. PubMed ID: 11792987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T; Zwick DL; Rothberg PG; Warady BA
    Pediatr Nephrol; 1999 Nov; 13(9):748-54. PubMed ID: 10603113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children.
    Faye A; Quartier P; Reguerre Y; Lutz P; Carret AS; Dehée A; Rohrlich P; Peuchmaur M; Matthieu-Boué A; Fischer A; Vilmer E
    Br J Haematol; 2001 Oct; 115(1):112-8. PubMed ID: 11722420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD; Preiksaitis JK;
    Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
    Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.